During the past decade, The Catholic University of Korea Incheon St. Mary's Hospital conducted 41 clinical trials. In the 10-year time frame, 41 clinical trials started and 9 clinical trials were completed, i.e. on average, 22% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 9 clinical trials were completed. i.e. 56.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Catholic University of Korea Incheon St. Mary's Hospital" #1 sponsor was "National Cancer Center, Korea" with 4 trials, followed by "Boryung Pharmaceutical Co., Ltd" with 3 trials sponsored, "Gilead Sciences" with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored and "Janssen Research & Development, LLC" with 3 trials sponsored. Other sponsors include 28 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Catholic University of Korea Incheon St. Mary's Hospital" #1 collaborator was "Dongnam Institute of Radiological & Medical Sciences" with 3 trials as a collaborator, "Incheon St.Mary's Hospital" with 3 trials as a collaborator, "Inha University Hospital" with 3 trials as a collaborator, "Chonnam National University Hospital" with 2 trials as a collaborator and "Chung-Ang University Hosptial, Chung-Ang University College of Medicine" with 2 trials as a collaborator. Other collaborators include 30 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "The Catholic University of Korea Incheon St. Mary's Hospital" are "Diphtheria" (3 trials), "Gastric Cancer" (3 trials), "Hepatocellular Carcinoma" (3 trials), "Tetanus" (3 trials) and "Breast Cancer" (2 trials). Many other conditions were trialed in "The Catholic University of Korea Incheon St. Mary's Hospital" in a lesser frequency.

Most popular intervention types in "The Catholic University of Korea Incheon St. Mary's Hospital" are "Drug" (27 trials), "Biological" (8 trials), "Other" (6 trials), "Procedure" (6 trials) and "Radiation" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Abrocitinib 200 mg" (2 trials), "Alectinib" (2 trials), "Bismuth-Containing Quadruple Therapy" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "The Catholic University of Korea Incheon St. Mary's Hospital" are 48 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "The Catholic University of Korea Incheon St. Mary's Hospital". 1 are not yet recruiting, 8 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in The Catholic University of Korea Incheon St. Mary's Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in The Catholic University of Korea Incheon St. Mary's Hospital, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 4 trials that are defined as “Not Applicable".